Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens
-
Published:2023-08-13
Issue:27
Volume:12
Page:
-
ISSN:2192-2640
-
Container-title:Advanced Healthcare Materials
-
language:en
-
Short-container-title:Adv Healthcare Materials
Author:
Karavasili Christina12ORCID,
Babaee Sahab123,
Kutty Shruti1,
Chu Jacqueline N.124,
Min Seokkee13,
Fitzgerald Nina1,
Morimoto Joshua1,
Inverardi Nicoletta1,
Traverso Giovanni123ORCID
Affiliation:
1. David H. Koch Institute for Integrative Cancer Research and Department of Chemical Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA
2. Division of Gastroenterology Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
3. Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA
4. Integrated Gastroenterology Consultants N. Chelmsford MA 01863 USA
Abstract
AbstractSimplification of complex medication regimens in polypharmacy positively contributes to treatment adherence and cost‐effective improved health outcomes. Even though fixed dose combination (FDC) drug products are the only currently available single dose poly‐pill regimens, the lack of flexibility in dose adjustment of a single drug in the combination limits their efficacy. To fill the existing gap in drug dose personalization and simplification of complex medication regimens commonly encountered in the treatment of cardiovascular disease, tuberculosis, and tapering of corticosteroid therapy, a modular titratable polypill approach that simultaneously addresses both aspects is proposed. The polypill consists of modular units that contain different drugs at incremental or decremental doses to be assembled in a single titratable polypill at the required dose for each drug through a stacking or interlocking process. The variable dose (VD) modular tablets are subjected to quality control tests and found to comply to pharmacopeia's acceptance criteria and requirements specified in the respective drug monographs. A cost‐effectiveness analysis is conducted supporting the VD strategy as cost‐effective compared to the FDC strategy and more effective and less expensive than standard of care. The VD approach stands to enable pill burden reduction, ease of administration, enhancement of treatment adherence, and potential cost‐saving benefits.
Funder
Department of Mechanical Engineering, College of Engineering, Michigan State University
Massachusetts Institute of Technology
Bill and Melinda Gates Foundation
Subject
Pharmaceutical Science,Biomedical Engineering,Biomaterials
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献